"Cost-Benefit Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.
| Descriptor ID |
D003362
|
| MeSH Number(s) |
N03.219.151.125
|
| Concept/Terms |
Cost-Benefit Analysis- Cost-Benefit Analysis
- Analyses, Cost-Benefit
- Analysis, Cost-Benefit
- Cost-Benefit Analyses
- Cost Benefit Analysis
- Analyses, Cost Benefit
- Analysis, Cost Benefit
- Cost Benefit Analyses
Cost-Utility Analysis- Cost-Utility Analysis
- Analyses, Cost-Utility
- Analysis, Cost-Utility
- Cost Utility Analysis
- Cost-Utility Analyses
Economic Evaluation- Economic Evaluation
- Economic Evaluations
- Evaluation, Economic
- Evaluations, Economic
Marginal Analysis- Marginal Analysis
- Analyses, Marginal
- Analysis, Marginal
- Marginal Analyses
Cost Benefit- Cost Benefit
- Costs and Benefits
- Benefits and Costs
|
Below are MeSH descriptors whose meaning is more general than "Cost-Benefit Analysis".
Below are MeSH descriptors whose meaning is more specific than "Cost-Benefit Analysis".
This graph shows the total number of publications written about "Cost-Benefit Analysis" by people in this website by year, and whether "Cost-Benefit Analysis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 2 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 9 | 9 |
| 2004 | 2 | 5 | 7 |
| 2005 | 2 | 8 | 10 |
| 2006 | 0 | 5 | 5 |
| 2007 | 0 | 5 | 5 |
| 2008 | 0 | 16 | 16 |
| 2009 | 0 | 11 | 11 |
| 2010 | 3 | 13 | 16 |
| 2011 | 1 | 14 | 15 |
| 2012 | 0 | 14 | 14 |
| 2013 | 0 | 14 | 14 |
| 2014 | 1 | 11 | 12 |
| 2015 | 0 | 12 | 12 |
| 2016 | 3 | 25 | 28 |
| 2017 | 3 | 12 | 15 |
| 2018 | 5 | 12 | 17 |
| 2019 | 6 | 21 | 27 |
| 2020 | 0 | 18 | 18 |
| 2021 | 0 | 9 | 9 |
| 2022 | 0 | 12 | 12 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cost-Benefit Analysis" by people in Profiles.
-
Willke RJ, Pizzi LT, Rand LZ, Neumann P. The Value of the Quality-Adjusted Life Years. Value Health. 2024 Jun; 27(6):702-705.
-
Dong S, Jutkowitz E, Giardina J, Bilinski A. Screening Strategies to Reduce COVID-19 Mortality in Nursing Homes. JAMA Health Forum. 2024 Apr 05; 5(4):e240688.
-
Rosen S, Blokhina E, Truong V, Bereznicka A, Gnatienko N, Quinn E, Lioznov D, Krupitsky E, Michals A, Lunze K, Samet JH. Comparative costs and potential affordability of a multifaceted intervention to improve treatment outcomes among people with HIV who inject drugs in Russia: economic evaluation of the LINC-II randomized controlled trial. J Int AIDS Soc. 2024 Feb; 27(2):e26208.
-
Kansal A, Latour JM, See KC, Rai S, Cecconi M, Britto C, Conway Morris A, Dominic Savio R, Nadkarni VM, Rao BK, Mishra R. Interventions to promote cost-effectiveness in adult intensive care units: consensus statement and considerations for best practice from a multidisciplinary and multinational eDelphi study. Crit Care. 2023 Dec 11; 27(1):487.
-
Perez-Troncoso D, Epstein D, Davies AH, Thapar A. Cost-effectiveness of carotid endarterectomy in symptomatic patients. Br J Surg. 2023 01 10; 110(2):193-199.
-
Torchia MT, Khan IA, Christensen DD, Moschetti WE, Fillingham YA. Universal Screening for Malnutrition Prior to Total Knee Arthroplasty Is Cost-Effective: A Markov Analysis. J Arthroplasty. 2023 03; 38(3):443-449.
-
Wender RC, Rendle KA. One Barrier to Colorectal Cancer Screening Eliminated: On to the Next. Cancer Prev Res (Phila). 2022 10 04; 15(10):641-644.
-
Olry de Labry-Lima A, Ponce-Polo A, Garc?a-Moch?n L, Ortega-Ortega M, P?rez-Troncoso D, Epstein D. Challenges for Economic Evaluations of Advanced Therapy Medicinal Products: A Systematic Review. Value Health. 2023 Jan; 26(1):138-150.
-
Ngabonzima A, Asingizwe D, Cechetto D, Mukunde G, Nyalihama A, Gakwerere M, Epstein DM. Evaluating the medical direct costs associated with prematurity during the initial hospitalization in Rwanda: a prevalence based cost of illness study. BMC Health Serv Res. 2022 Jul 27; 22(1):953.
-
Peel JK, Neves Miranda R, Naimark D, Woodward G, Mamas MA, Madan M, Wijeysundera HC. Financial Incentives for Transcatheter Aortic Valve Implantation in Ontario, Canada: A Cost-Utility Analysis. J Am Heart Assoc. 2022 04 19; 11(8):e025085.